Research programme: nanomedicines - Pfizer/Roche
Latest Information Update: 28 Jul 2018
At a glance
- Originator BIND Therapeutics; Roche
- Developer Pfizer; Roche
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified